Cargando…
Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571673/ https://www.ncbi.nlm.nih.gov/pubmed/36233537 http://dx.doi.org/10.3390/jcm11195669 |
_version_ | 1784810420913045504 |
---|---|
author | Burdge, Gemma Hardman, Alice Carbery, Isabel Broglio, Giacomo Greer, Dan Selinger, Christian P. |
author_facet | Burdge, Gemma Hardman, Alice Carbery, Isabel Broglio, Giacomo Greer, Dan Selinger, Christian P. |
author_sort | Burdge, Gemma |
collection | PubMed |
description | Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors. |
format | Online Article Text |
id | pubmed-9571673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95716732022-10-17 Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations Burdge, Gemma Hardman, Alice Carbery, Isabel Broglio, Giacomo Greer, Dan Selinger, Christian P. J Clin Med Article Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors. MDPI 2022-09-26 /pmc/articles/PMC9571673/ /pubmed/36233537 http://dx.doi.org/10.3390/jcm11195669 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Burdge, Gemma Hardman, Alice Carbery, Isabel Broglio, Giacomo Greer, Dan Selinger, Christian P. Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations |
title | Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations |
title_full | Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations |
title_fullStr | Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations |
title_full_unstemmed | Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations |
title_short | Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations |
title_sort | uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571673/ https://www.ncbi.nlm.nih.gov/pubmed/36233537 http://dx.doi.org/10.3390/jcm11195669 |
work_keys_str_mv | AT burdgegemma uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations AT hardmanalice uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations AT carberyisabel uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations AT brogliogiacomo uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations AT greerdan uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations AT selingerchristianp uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations |